Adam Asch

893 citations

27 papers · 689 indexed · h-index 8

Impact in

Immunology and Allergy top 2%
- Cell Adhesion Molecules Research
Immunology top 10%
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology

Papers in

Genetics 8
- Chronic Lymphocytic Leukemia Research 6
Hematology 8
- Acute Myeloid Leukemia Research 6
- Chronic Myeloid Leukemia Treatments 3

Co-authors: Elizabeth Sánchez S Srimal James Gailit Samuel D. Wright Claire Farber Carl Nathan Lynda Kabbash David N. Posnett
Journals: Annals of Oncology (3 papers)HemaSphere (2 papers)International Journal of Gynecological Cancer (1 paper)British Journal of Haematology (1 paper)The Journal of Cell Biology (1 paper)
Partner nations: United States United Kingdom Canada

In The Last Decade

Adam Asch

25 papers receiving 675 citations

Peers

Countries citing papers authored by Adam Asch

Since Specialization

Citations

This map shows the geographic impact of Adam Asch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Asch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Asch more than expected).

Fields of papers citing papers by Adam Asch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Asch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Asch. The network helps show where Adam Asch may publish in the future.

Co-authors

The 25 scholars most cited alongside Adam Asch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adam Asch Line = papers co-authored together Adam Asch links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas British Journal of Haematology ·Jacob D. Soumerai, Catherine Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L. Tsai, Thomas Jandl, Izidore S. Lossos, Vaishalee P. Kenkre, Farrukh T. Awan, William Novotny, Jane Huang, Miao Lü, Prabhu Rajagopalan, Richard Ghalie, Andrew D. Zelenetz	2024	3
2	Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models Cells ·Surya P. Singh, Gopal Pathuri, Adam Asch, Chinthalapally V. Rao, Venkateshwar Madka	2024	2
3	Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML Journal of Clinical Oncology ·Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, Nikolai A. Podoltsev, José C. Cruz, Tara L. Lin, Gary J. Schiller, Joseph G. Jurcic, Adam Asch, Ruishan Wu, Jason E. Hill, Stanley C. Gill, Angela James, Elizabeth Rich, Nahla Hasabou, Alexander E. Perl, Mark J. Levis	2023	27
4	1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors Annals of Oncology ·Víctor Moreno, Emiliano Calvo, Adam Asch, Marcus O. Butler, Jon Zugazagoitia, John A. Charlson, Andrés Cervantes, Brian A. Van Tine, David H. Aggen, Jade Clarke, Melissa L. Johnson, Megan Wileman, Andrew R. Liddle, R. Naidoo, Francine Brophy, M. J. Rosenberg, David A. Jolliffe, David E. Williams, E. Norry, David S. Hong	2023	6
5	Impact of primary organ site of involvement by peripheral T‐cell lymphoma not otherwise specified on survival Cancer Medicine ·Olivia Davis, Derek Truong, Silas Day, Manu Pandey, Sami Ibrahimi, Mohamad Khawandanah, Jennifer Holter‐Chakrabarty, Adam Asch, Taha Al‐Juhaishi	2023	2
6	Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·Kira MacDougall, Silas Day, Spencer R. Hall, Yan D. Zhao, Manu Pandey, Sami Ibrahimi, Mohamad Khawandanah, Jennifer Holter Chakrabarty, Adam Asch, Ryan David Nipp, Taha Al‐Juhaishi	2023	3
7	2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer International Journal of Gynecological Cancer ·Kathleen N. Moore, Adam Asch, Víctor Moreno, Emiliano Calvo, Marcus O. Butler, Jon Zugazagoitia, David S. Hong, Ahmed M. Galal, L. Ostios, Maria J. de Miguel, Quan Lin, Thejo Annareddy, Francine Brophy, Marisa Rosenberg, Theresa Seiders, Revashnee Naidoo, Natalie Bath, José Saro, Elliot Norry, Jeffrey Clarke	2022	1
8	Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial The Lancet Oncology ·John M. Pagel, Jacob D. Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P. Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li, Andrew D. Zelenetz	2022	16
9	AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results Clinical Lymphoma Myeloma & Leukemia ·Naval Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam Asch, Gabriel N. Mannis, Wanxing Chai‐Ho, Tiffany Tanaka, Terrence Bradley, Deepa Jeyakumar, Eunice S. Wang, Guan Xing, Mark P. Chao, Giri Ramsingh, Camille Renard, Indu Lal, Joshua F. Zeidner, David A. Sallman	2022	5
10	Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma Transplant Immunology ·Amany R. Keruakous, Adam Asch, Raid Aljumaily, Daniel Zhao, Carrie Yuen	2022	7
11	MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results Clinical Lymphoma Myeloma & Leukemia ·David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver	2022	2
12	735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors Annals of Oncology ·David S. Hong, Adam Asch, Emiliano Calvo, Jon Zugazagoitia, John A. Charlson, Marcus O. Butler, Víctor Moreno, Andrés Cervantes, Brian Andrew Van Tine, Donald P. Lawrence, Melissa L. Johnson, Qiaoming Lin, Thejonatha Annareddy, F. Brophy, Robyn Broad, A. Derrac Soria, J-M. Navenot, Jose Saro, E. Norry, Jeffrey Clarke	2022	6
13	540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4 Annals of Oncology ·David S. Hong, Jeffrey Clarke, Adam Asch, John A. Charlson, Tanner M. Johanns, Emiliano Calvo, Valentina Boni, Maria J. de Miguel, Víctor Moreno, Donald P. Lawrence, Marcus O. Butler, Jon Zugazagoitia, Mariela A. Blum Murphy, Partow Kebriaei, George R. Blumenschein, Qinlu Lin, H. Danesi, E. Norry	2021	6
14	S878 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS HemaSphere ·David A. Sallman, Will Donnellan, Adam Asch, D. Lee, Monzr Al Malki, Daniel A. Pollyea, Swetha Kambhampati, Rami S. Komrokji, Joanna Van Elk, M. Lin, Balaji Agoram, J. Chen, Jens Volkmer, Chris H. Takimoto, Mark P. Chao, Paresh Vyas	2019	9
15	S867 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS HemaSphere ·Ranjana H. Advani, Nancy L. Bartlett, Shannon E. Smith, Mark Roschewski, Leslie Popplewell, Ian W. Flinn, Graham P. Collins, Nilanjan Ghosh, Ann S. LaCasce, Adam Asch, J. Kline, Murali Kesavan, T. Tran, Judith Lynn, J. Huang, Balaji Agoram, Jens-Peter Volkmer, Chris H. Takimoto, Meng‐Yao Chao, Amitkumar Mehta	2019	2
16	THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS Hematological Oncology ·Ranjana H. Advani, Nancy L. Bartlett, Sonali M. Smith, Mark Roschewski, Leslie Popplewell, Ian W. Flinn, Graham P. Collins, Nilanjan Ghosh, Ann S. LaCasce, Adam Asch, J. Kline, M. Kesevan, T. Tran, Judith Lynn, J. Huang, Balaji Agoram, Jens-Peter Volkmer, Chris H. Takimoto, Mark P. Chao, Amitkumar Mehta	2019	21
17	Paracrine Suppression of VEGF Secretion by Erythropoietin Inhibits Tumor Growth. Blood ·Carroll Smith, Kenneth J. Salleng, Vaia Y. Sigounas, Adam Asch, George Sigounas	2007	1
18	MTO volume 14 issue 6 Cover and Front matter Microscopy Today ·Matthew M. Nowell, Martina Chui-Sabourin, John Carpenter, Vinayak P. Dravid, Adam Asch, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2006	1
19	T-cell antigen receptor Vβ subsets are not preferentially deleted in AIDS AIDS ·David N. Posnett, Shara Kabak, Andrew S. Hodtsev, Eileen A. Goldberg, Adam Asch	1993	54
20	Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. The Journal of Cell Biology ·Carl Nathan, S Srimal, Claire Farber, Elizabeth Sánchez, Lynda Kabbash, Adam Asch, James Gailit, Samuel D. Wright	1989	495

About Adam Asch

Adam Asch is a scholar working on Genetics, Hematology, Immunology, Oncology and Virology, having authored 27 papers that have together received 689 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Chronic Lymphocytic Leukemia Research (6 papers), CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (5 papers), Phagocytosis and Immune Regulation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Research and Treatments (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). The work is most often cited by research in Immunology and Allergy (289 citations), Immunology (371 citations), Virology (50 citations), Hematology (118 citations) and Genetics (40 citations). Adam Asch has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Elizabeth Sánchez, S Srimal, James Gailit, Samuel D. Wright, Claire Farber, Carl Nathan, Lynda Kabbash, David N. Posnett, Andrew S. Hodtsev and Shara Kabak. Their work appears in journals such as Annals of Oncology, HemaSphere, International Journal of Gynecological Cancer, British Journal of Haematology and The Journal of Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact